Satsuma pulped as acute migraine drug flunks phase 3 trialShares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed Share XSatsuma pulped as acute migraine drug flunks phase 3 trialhttps://pharmaphorum.com/news/satsuma-pulped-as-acute-migraine-drug-flunks-phase-3-trial/
FDA starts review of Pfizer, Lilly’s non-opioid painkillerAfter years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, Share XFDA starts review of Pfizer, Lilly’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-starts-review-of-pfizer-lillys-non-opioid-painkiller/
Exclusive Speaker Interview with Stephen Hunt, Professor, UCL, ahead of Pain TherapeuticsExclusive Speaker Interview with Stephen Hunt Share XExclusive Speaker Interview with Stephen Hunt, Professor, UCL, ahead of Pain Therapeuticshttps://pharmaphorum.com/partner-content/exclusive-speaker-interview-with-stephen-hunt-professor-ucl-ahead-of-pain-therapeutics/
Durect’s post-op painkiller splits FDA advisory panelAs the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new Share XDurect’s post-op painkiller splits FDA advisory panelhttps://pharmaphorum.com/news/durects-post-op-painkiller-splits-fda-advisory-panel/
Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
Kaia to develop back pain app for US market after trial successDigital therapeutics company Kaia Health has announced results from the first randomised controlled trial of its back pain Share XKaia to develop back pain app for US market after trial successhttps://pharmaphorum.com/news/kaia-to-develop-back-pain-app-for-us-market-after-trial-success/
FDA rejects Heron’s non-opioid painkillerShares in US biotech Heron Therapeutics were sharply down yesterday after the FDA rejected its post-operative painkiller, saying Share XFDA rejects Heron’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-rejects-herons-non-opioid-painkiller/
Drug firm prosecuted for distributing opioids illegallyA US-based drug distribution company and two former executives are being prosecuted for transporting medicines to pharmacies allegedly Share XDrug firm prosecuted for distributing opioids illegallyhttps://pharmaphorum.com/news/drug-firm-prosecuted-for-distributing-opioids-illegally/
R&D round-up: Non-opioid painkiller space heats upAs the MHRA announced that it would be convening an Expert Working Group (EWG) to assess the risks Share XR&D round-up: Non-opioid painkiller space heats uphttps://pharmaphorum.com/views-and-analysis/rd-roundup-non-opioid-painkiller-space-heats-up/